This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letters  • Similar articles in JAMA  Topic Collections  • Viral Infections  • Statistics and Research Methods  • Transplantation  • Transplantation, Other  • Endocrine Diseases  • Diabetes Mellitus  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: In response to Dr Gitelman and colleagues, most of the 160 screened patients were not eligible for the study either because of disease diagnosed for more than 6 weeks, absence of positive results from an anti–glutamic acid decarboxylase test, presence of previous ketoacidosis, or absence of evaluation for ketoacidosis. Approximately 30% of the patients eligible for the study were not willing to accept the risks of the procedure.

We performed weekly monitoring for cytomegalovirus infection in all patients. None of them developed primary infection or reactivation of cytomegalovirus or Epstein-Barr virus. We support research efforts to expand on our work on immune intervention in type 1 diabetes mellitus, with a goal of obtaining the same or better results with less toxicity.

Drs Olmos and Borzone request an actuarial analysis of our data. The data necessary for deriving an actuarial analysis curve did not exist in Table 1. First, . . . [Full Text of this Article]

Júlio C. Voltarelli, MD, PhD
jcvoltar@fmrp.usp.br
Department of Clinical Medicine

Edson Z. Martinez, PhD
Department of Social Medicine
School of Medicine of Ribeirão Preto
University of São Paulo
Ribeirão Preto, Brazil

Richard K. Burt, MD
Division of Immunotherapy
Northwestern University Feinberg School of Medicine
Chicago, Illinois

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus
Júlio C. Voltarelli, Carlos E. B. Couri, Ana B. P. L. Stracieri, Maria C. Oliveira, Daniela A. Moraes, Fabiano Pieroni, Marina Coutinho, Kelen C. R. Malmegrim, Maria C. Foss-Freitas, Belinda P. Simões, Milton C. Foss, Elizabeth Squiers, and Richard K. Burt
JAMA. 2007;297(14):1568-1576.
ABSTRACT | FULL TEXT  

RELATED LETTERS

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus
Stephen E. Gitelman, Michael J. Haller, and Desmond Schatz
JAMA. 2009;302(6):624.
EXTRACT | FULL TEXT  

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus
Pablo R. Olmos and Gisella Borzone
JAMA. 2009;302(6):624.
EXTRACT | FULL TEXT